Posts
Four Motors of Europe visiting Rotterdam, Delft and Leiden
This week, InnovationQuarter and the Province of Zuid-Holland were delighted to host a large business delegation from Baden-Württemberg, Catalonia, Lombardy and Auvergne-Rôhne Alpes. These leading industrial regions have a 30-year-old partnership, called ‘Four Motors for Europe’. How can we strengthen cooperation with partners in the Netherlands to tackle our shared challenges in public health and electro-mobility? The ‘Four Motors’, led by Ms. Katrin Schütz (State Secretary of Economic Affairs, Labour and Housing for Baden-Württemberg), were looking forward to explore this question together with innovative companies and leading knowledge institutions in Zuid-Holland.
BioGeneration Ventures Fund III reaches € 82 million in final close
BioGeneration Ventures (BGV) announces the final closing of its third fund, BGV III at EUR 82 million. Due to strong market interest, the fund has exceeded its original target of EUR 50 million.
Groundbreaking Snake Venom Inspired Approach to Restore Blood Clotting in Patients Using Anticoagulants
VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced the publication in Nature Communications of a ground breaking LUMC study(1) on modified human factor X as a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants. This new therapeutic factor X was inspired by a snake venom protein, and is the lead product in development of VarmX, a pharmaceutical LUMC spin off.
VarmX raises seed capital for development of modified blood coagulation factor X
VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced the final closing of its seed financing round. New participants providing this seed capital are Dutch VC BioGeneration Ventures (BGV) and regional economic development agency InnovationQuarter. The funds will enable VarmX to advance its lead compound PseudoXa, a modified factor X as a safe and effective factor Xa inhibitor reversal agent.